De novo BD or exacerbations of pre-existing BD have been reported following treatment with several biologic agents, particularly anti-IL-17 therapies such as secukinumab and ixekizumab [22,23,24,25,29,85,86,87,88,89,90]. This evidence concerns the gene IL17A and Behcet disease.